We have been working with AMAG Pharmaceuticals, our Vyleesi North American partner, to support the Vyleesi New Drug Application which AMAG submitted to the FDA in March 2018. The NDA was accepted for review by the FDA in June 2018, and the PDUFA date of Vyleesi NDA is June 23, 2019. In November 2018, the FDA requested additional data from a clinical study assessing 24-hour ambulatory blood pressure with short-term daily use of Vyleesi. The requested study has been completed.